Indications and clinical use:
Victoza® is indicated for once-daily administration for the treatment of adults with type 2 diabetes to improve glycemic control in combination with:
Metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.
Metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.
Metformin and a basal insulin, when diet and exercise plus dual therapy with Victoza® and metformin do not achieve adequate glycemic control.
Not a substitute for insulin. Should not be used in type 1 diabetes.
Patients >70 years may experience more gastrointestinal side effects.
Victoza® is not indicated for use in pediatric patients.
Patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnant or nursing women
Most serious warnings and precautions:
Risk of thyroid C-cell tumours: In both genders of rats and mice, liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumours. Patients should be counselled regarding the risk and symptoms of thyroid tumours.
Other relevant warnings and precautions:
CV effects: Increased heart rate, PR interval prolongation
Should not be used for treatment of diabetic ketoacidosis
Should not be administered intravenously or intramuscularly
Hypoglycemia in combination with a sulfonylurea
Pen for individual use only
Recent MI, unstable angina and congestive heart failure
Hepatic and renal impairment
For more information:
Please consult the product monograph at http://novonordisk.ca/PDF_Files/our_products/Victoza/Victoza_PM_EN.pdf for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this advertisement.
The product monograph is also available by calling us at 1-800-465-4334.